Is Phibro Animal Health Corp. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Phibro Animal Health Corp. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 21, a Price to Book Value of 3.67, and an EV to EBITDA of 9.97. In comparison to its peers, Phibro's valuation is more favorable than Soleno Therapeutics, Inc., which has a P/E of -21.86, and Arcutis Biotherapeutics, Inc., with a P/E of -22.20.
Phibro has demonstrated strong performance, with a year-to-date return of 89.14% compared to the S&P 500's 13.30%, and a one-year return of 63.05% against the S&P 500's 14.08%. These figures suggest that the stock is performing well relative to the broader market, reinforcing the notion that it is fairly valued at this time.